Start here if you're new
what it is
Annovis Bio is trying to make a pill for brain diseases like Alzheimer's and Parkinson's.
how it gets paid
Last year Annovis Bio made $0 in revenue.
what just happened
Latest quarter showed $0 revenue and -$1.01 EPS (q)—versus the score-strip ~-$2.31 FY2024 EPS est. (different period: one quarter vs full-year consensus).
At a glance
C++ balance sheet — some cracks in the foundation
45/100 earnings predictability — expect surprises
-$2.31 fy2024 eps est
1.9 beta
~$67M market cap
xvary composite: 32/100 — weak
What they do
Annovis Bio is trying to make a pill for brain diseases like Alzheimer's and Parkinson's.
Your edge here is not sales. It is one lead drug, buntanetap, that is taken by mouth and reaches the brain. A safety board backed it after 6 months in the late-stage trial, and the FDA has lined up on two drug-approval paths. That is a real clinical signal against $0 revenue, but it is still a signal, not a business.
How they make money
$0
annual revenue
The products that matter
lead drug candidate
buntanetap
$0 revenue today
this is the asset. It produces $0 in revenue today, which means almost all of the company's value comes from clinical potential rather than commercial execution.
binary setup
Alzheimer's program
buntanetap
FDA filing target: end 2026
management's target is an FDA filing by the end of 2026. For you as a shareholder, that makes late-stage Alzheimer's data the clock the whole stock is trading on.
phase 3 focus
Parkinson's program
buntanetap
second shot on goal
the same lead asset is also being developed for Parkinson's. Two indications help the narrative, but they still roll up to one molecule and one core scientific bet.
same asset risk
Key numbers
$67M
company value
That is the whole market's price for the business. One trial matters more than years of chatter.
$0
annual revenue
No sales means no cushion. Value depends on trial results, not customer demand.
-$2.31
2024 loss per share
Consensus-style figures in the data stack point to about a $2.31 loss per share in 2024. That is the burn rate in plain English.
1.9
volatility
The stock swings about 90% more than the market. Your entry price will matter a lot.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ANVS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest quarter showed $0 revenue and -$1.01 earnings per share (a loss, not profit), so the business is still all science, no sales.
EDGAR shows annual revenue at $0. VL has FY2024 loss per share at -$2.31, while Yahoo says trailing loss per share is -$1.48. That is three sources pointing at the same problem.
$0
revenue
-$1.01
eps (q)
-$2.31
fy loss/sh (est.)
the number that mattered
The number that matters is $0 revenue. Without sales, the stock trades on trial data and financing, not operating results.
source: EDGAR, VL, Yahoo Finance, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
ANVS is not dealing with generic biotech risk. The three threats are specific and connected: buntanetap has to work, the company has to stay funded long enough to prove it, and the stock has to survive the volatility that comes with both.
high
Financing treadmill
Annovis raised about $9.4M in October 2025 across two stock sales to investors. That is fresh equity, not money from customers.
Another raise at that scale would mean roughly $9.4M of new shares and more dilution, your slice gets smaller.
high
One-drug dependence
The company has $0 annual revenue and 8 employees. That means buntanetap is the whole story until something else lands.
A failed late-stage trial puts the full $67M value at risk.
med
Wild price swings
VL shows volatility at 1.9 and price stability at 5 out of 100. That is a stock that moves about 90% more than the market.
A 10% market move can look like about 19% here.
If buntanetap stumbles, there is no second business to catch you.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical milestone
late-stage buntanetap data across Alzheimer's and Parkinson's
This is the main event. Management is targeting an FDA filing by the end of 2026, so data quality decides whether the valuation starts to look cheap or deserved.
capital
cash burn versus the $19.5M reserve
The next quarterly reports matter less for revenue, because there is none, and more for runway. If cash drains faster than expected, dilution moves from a risk to a near-term event.
timeline
whether the end-2026 FDA filing target still looks realistic
Target dates are only useful when the company keeps hitting the steps before them. If the timeline starts slipping, the stock will notice before the press release says it plainly.
street expectations
whether the $10.00 median target from 8 analysts holds up
Analyst targets in biotech are often scenario math wearing a suit. If those targets start moving down as readouts approach, that tells you the street is cutting probability, not just changing style points.
Analyst rankings
earnings predictability
45 / 100
reported results are harder to predict. in human-speak: expect noisy quarters because trial timing matters more than operations
analyst coverage
8
eight analysts cover a $67M biotech. that is a lot of scenario math for a very small company
median price target
$10.00 +322%
based on the current $2.37 share price, the median target implies outcome-driven upside, not current operating strength
source: institutional data
Institutional activity
institutional ownership data for ANVS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive